1077.7000 -29.50 (-2.66%)
NSE Aug 25, 2025 15:31 PM
Volume: 118.0K
 

1077.70
-2.66%
ICICI Securities Limited
Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.
Tatva Chintan Pharma Chem Ltd. has gained 52.17% in the last 6 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended